Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Judith Karp
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Anatomy
Procedures
Concepts & Ideas
Physiology
Sign-in to see full Profile
Network (preview)
24
Smith, Douglas
19
Kaufmann, Scott
18
Lancet, Jeffrey
17
Merz, William
15
Gojo, Ivana
15
Gore, Steven
10
Greer, Jacqueline
10
Burke, PJ
8
Tidwell, Michael
7
Wright, John
7
Giles, Francis
7
Dick, James
7
Donehower, Ross
7
Loegering, David
7
Jones, Richard
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Judith Karp (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Ye Ying; McDevitt Michael A; Guo Mingzhou; Zhang Wei; Galm Oliver; Gore Steven D; Karp Judith E; Maciejewski Jaroslaw P; Kowalski Jeanne; Tsai Hua-Ling; Gondek Lukasz P; Tsai Hsing-Chen; Wang Xiaofei; Hooker Craig; Smith B Douglas; Carraway Hetty E; Herman James G
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
Cancer research 2009;69(21):8482-90.
-
2009: Tiu Ramon V; Gondek Lukasz P; O'Keefe Christine L; Huh Jungwon; Sekeres Mikkael A; Elson Paul; McDevitt Michael A; Wang Xiao Fei; Levis Mark J; Karp Judith E; Advani Anjali S; Maciejewski Jaroslaw P
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(31):5219-26.
-
2009: Wahner Hendrickson Andrea E; Haluska Paul; Schneider Paula A; Loegering David A; Peterson Kevin L; Attar Ricardo; Smith B Douglas; Erlichman Charles; Gottardis Marco; Karp Judith E; Carboni Joan M; Kaufmann Scott H
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.
Cancer research 2009;69(19):7635-43.
-
2009: Fathi Amir T; Karp Judith E
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.
Current oncology reports 2009;11(5):346-52.
-
2009: Karp Judith E; Flatten Karen; Feldman Eric J; Greer Jacqueline M; Loegering David A; Ricklis Rebecca M; Morris Lawrence E; Ritchie Ellen; Smith B Douglas; Ironside Valerie; Talbott Timothy; Roboz Gail; Le Son B; Meng Xue Wei; Schneider Paula A; Dai Nga T; Adjei Alex A; Gore Steven D; Levis Mark J; Wright John J; Garrett-Mayer Elizabeth; Kaufmann Scott H
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Blood 2009;113(20):4841-52.
-
2009: Pratz Keith W; Cortes Jorge; Roboz Gail J; Rao Niranjan; Arowojolu Omotayo; Stine Adam; Shiotsu Yukimasa; Shudo Aiko; Akinaga Shiro; Small Donald; Karp Judith E; Levis Mark
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
Blood 2009;113(17):3938-46.
-
2009: Lancet Jeffrey E; Karp Judith E
Novel postremission strategies in adults with acute myeloid leukemia.
Current opinion in hematology 2009;16(2):105-11.
-
2009: Smith B Douglas; Karp Judith E
What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.
Clinical lymphoma & myeloma 2009;9 Suppl 3():S296-301.
-
2008: Karp Judith
Future research directions for the treatment of AML.
Clinical advances in hematology & oncology : H&O 2008;6(11):8-10.
-
2008: Karp Judith E; Lancet Jeffrey E
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.
Biologics : targets & therapy 2008;2(3):491-500.
-
2008: Vaughan William P; Karp Judith E
The long road to a cure for acute myelocytic leukemia: from intensity to specificity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3475-7.
-
2008: Karp Judith E; Smith B Douglas; Gojo Ivana; Lancet Jeffrey E; Greer Jacqueline; Klein Maureen; Morris Larry; Levis Mark J; Gore Steven D; Wright John J; Garrett-Mayer Elizabeth
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3077-82.
-
2008: Raponi Mitch; Lancet Jeffrey E; Fan Hongtao; Dossey Lesley; Lee Grace; Gojo Ivana; Feldman Eric J; Gotlib Jason; Morris Lawrence E; Greenberg Peter L; Wright John J; Harousseau Jean-Luc; Löwenberg Bob; Stone Richard M; De Porre Peter; Wang Yixin; Karp Judith E
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Blood 2008;111(5):2589-96.
-
2008: Segal Brahm H; Freifeld Alison G; Baden Lindsey Robert; Brown Arthur E; Casper Corey; Dubberke Erik; Gelfand Michael; Greene John N; Ison Michael G; Ito James I; Karp Judith E; Kaul Daniel R; King Earl; Mackler Emily; Marcucci Guido; Montoya Jose G; Engemann Ashley Morris; Rolston Ken; The Angelina S
Prevention and treatment of cancer-related infections.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(2):122-74.
-
2008: Yu Wenqiang; Gius David; Onyango Patrick; Muldoon-Jacobs Kristi; Karp Judith; Feinberg Andrew P; Cui Hengmi
Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA.
Nature 2008;451(7175):202-6.
-
2008: Karp Judith E; Giles Francis J; Gojo Ivana; Morris Lawrence; Greer Jacqueline; Johnson Bonny; Thein Mya; Sznol Mario; Low Jennifer
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Leukemia research 2008;32(1):71-7.
-
2007: Meng Xue Wei; Lee Sun-Hee; Dai Haiming; Loegering David; Yu Chunrong; Flatten Karen; Schneider Paula; Dai Nga T; Kumar Shaji K; Smith B Douglas; Karp Judith E; Adjei Alex A; Kaufmann Scott H
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
The Journal of biological chemistry 2007;282(41):29831-46.
-
2007: Karp Judith E; Lancet Jeffrey E
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Cancer investigation 2007;25(6):484-94.
-
2007: Lin T L; Vala M S; Barber J P; Karp J E; Smith B D; Matsui W; Jones R J
Induction of acute lymphocytic leukemia differentiation by maintenance therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(9):1915-20.
-
2007: Karp Judith E; Ricklis Rebecca M; Balakrishnan Kumudha; Briel Janet; Greer Jacqueline; Gore Steven D; Smith B Douglas; McDevitt Michael A; Carraway Hetty; Levis Mark J; Gandhi Varsha
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
Blood 2007;110(6):1762-9.
-
2007: Gojo Ivana; Tidwell Michael L; Greer Jacqueline; Takebe Naoko; Seiter Karen; Pochron Mary F; Johnson Bonny; Sznol Mario; Karp Judith E
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Leukemia research 2007;31(9):1165-73.
-
2007: Karp Judith E; Smith B Douglas; Levis Mark J; Gore Steven D; Greer Jacqueline; Hattenburg Catherine; Briel Janet; Jones Richard J; Wright John J; Colevas A Dimitri
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4467-73.
-
2007: McDevitt M A; Condon M; Stamberg J; Karp J E; McDiarmid M
Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.
Mutation research 2007;629(1):24-31.
-
2007: Gojo Ivana; Jiemjit Anchalee; Trepel Jane B; Sparreboom Alex; Figg William D; Rollins Sandra; Tidwell Michael L; Greer Jacqueline; Chung Eun Joo; Lee Min-Jung; Gore Steven D; Sausville Edward A; Zwiebel James; Karp Judith E
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood 2007;109(7):2781-90.
-
2007: Lancet Jeffrey E; Gojo Ivana; Gotlib Jason; Feldman Eric J; Greer Jacqueline; Liesveld Jane L; Bruzek Laura M; Morris Lawrence; Park Youn; Adjei Alex A; Kaufmann Scott H; Garrett-Mayer Elizabeth; Greenberg Peter L; Wright John J; Karp Judith E
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Blood 2007;109(4):1387-94.
-
2007: Giles Francis; Rizzieri David; Karp Judith; Vey Norbert; Ravandi Farhad; Faderl Stefan; Khan Khuda Dad; Verhoef Gregor; Wijermans Pierre; Advani Anjali; Roboz Gail; Kantarjian Hagop; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon M G J; Karsten Verena; Cahill Ann; Albitar Maher; Mufti Ghulam; O'Brien Susan
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):25-31.
-
2006: Giles Francis; Verstovsek Srdan; Faderl Stefan; Vey Norbert; Karp Judy; Roboz Gail; Khan Khuda Dan; Cooper Maureen; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon; Karsten Verena; Cahill Ann; Albitar Maher; Kantarjian Hagop; O'Brien Susan; Feldman Eric
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia research 2006;30(12):1591-5.
-
2006: Levis Mark; Brown Patrick; Smith B Douglas; Stine Adam; Pham Rosalyn; Stone Richard; Deangelo Daniel; Galinsky Ilene; Giles Frank; Estey Elihu; Kantarjian Hagop; Cohen Pamela; Wang Yanfeng; Roesel Johannes; Karp Judith E; Small Donald
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Blood 2006;108(10):3477-83.
-
2006: Karp Judith E; Smith B Douglas
Exploiting oxidative damage to overcome resistance.
Leukemia research 2006;30(10):1213-4.
-
2006: Acharya Milin R; Karp Judith E; Sausville Edward A; Hwang Kyunghwa; Ryan Qin; Gojo Ivana; Venitz Jurgen; Figg William D; Sparreboom Alex
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs 2006;24(5):367-75.
-
2006: Karp Judith E; Smith B Douglas
Developmental clinical trials: building one step at a time.
Leukemia research 2006;30(7):765-6.
-
2006: Gore Steven D; Baylin Stephen; Sugar Elizabeth; Carraway Hetty; Miller Carole B; Carducci Michael; Grever Michael; Galm Oliver; Dauses Tianna; Karp Judith E; Rudek Michelle A; Zhao Ming; Smith B Douglas; Manning Jasper; Jiemjit Anchalee; Dover George; Mays Abbie; Zwiebel James; Murgo Anthony; Weng Li-Jun; Herman James G
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Cancer research 2006;66(12):6361-9.
-
2006: Steensma D P; McClure R F; Karp J E; Tefferi A; Lasho T L; Powell H L; DeWald G W; Kaufmann S H
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(6):971-8.
-
2006: Chandra Joya; Tracy Jeannette; Loegering David; Flatten Karen; Verstovsek Srdan; Beran Miloslav; Gorre Mercedes; Estrov Zeev; Donato Nicholas; Talpaz Moshe; Sawyers Charles; Bhalla Kapil; Karp Judith; Sausville Edward; Kaufmann Scott H
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood 2006;107(6):2501-6.
-
2005: Karp Judith E; Lancet Jeffrey E
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Future oncology (London, England) 2005;1(6):719-31.
-
2005: Karp Judith E; Passaniti Antonino; Gojo Ivana; Kaufmann Scott; Bible Keith; Garimella Tushar S; Greer Jacqueline; Briel Janet; Smith B Douglas; Gore Steven D; Tidwell Michael L; Ross Douglas D; Wright John J; Colevas A Dimitrios; Bauer Kenneth S
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8403-12.
-
2005: Karp Judith E; Lancet Jeffrey E
Targeting the process of farynesylation for therapy of hematologic malignancies.
Current molecular medicine 2005;5(7):643-52.
-
2005: Karp Judith E
Farnesyl transferase inhibition in hematologic malignancies.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3 Suppl 1():S37-40.
-
2005: Kaufmann Scott H; Karp Judith E; Letendre Louis; Kottke Timothy J; Safgren Stephanie; Greer Jackie; Gojo Ivana; Atherton Pamela; Svingen Phyllis A; Loegering David A; Litzow Mark R; Sloan Jeff A; Reid Joel M; Ames Matthew M; Adjei Alex A; Erlichman Charles
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6641-9.
-
2005: Lancet Jeffrey E; Karp Judith E
Farnesyl transferase inhibitors in myeloid disorders.
Oncology (Williston Park, N.Y.) 2005;19(8):1043-9; discussion 1049-50, 1053-4.
-
2005: Mesa Ruben A; Loegering David; Powell Heather L; Flatten Karen; Arlander Sonnet J H; Dai Nga T; Heldebrant Michael P; Vroman Benjamin T; Smith B Douglas; Karp Judith E; Eyck Cynthia J Ten; Erlichman Charles; Kaufmann Scott H; Karnitz Larry M
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Blood 2005;106(1):318-27.
-
2005: Gore Steven D; Smith B Douglas; Gojo Ivana; Grever Michael; Kaufmann Scott H; Letendre Louis; Leonard Debra G B; Marcucci Guido; Miller Carole B; Morris Lawrence; Piantadosi Steven; Prior Thomas; Stock Wendy; Karp Judith E
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
American journal of hematology 2005;79(2):119-27.
-
2005: Smith B Douglas; Karp Judith E
Curing acute myelogenous leukemia: still a major challenge.
Leukemia research 2005;29(6):607-8.
-
2005: Karp Judith E; Smith B Douglas
Trying to improve clinical outcome in AML: lessons from negative trials.
Leukemia research 2005;29(6):603-4.
-
2005: Bao Ting; Smith B Douglas; Karp Judith E
New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.
Clinical advances in hematology & oncology : H&O 2005;3(4):287-96, 302.
-
2005: Bauer Kenneth S; Karp Judith E; Garimella Tushar S; Wu Suhlan; Tan Ming; Ross Douglas D
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
Leukemia research 2005;29(3):263-71.
-
2005: Smith B D; Bao T; Karp J E
New concepts in the treatment of acute myeloid malignancies: selected pathways for targeted therapy.
Journal of biological regulators and homeostatic agents 2005;19(1-2):23-32.
-
2005: Chung Eun Joo; Lee Sunmin; Sausville Edward A; Ryan Qin; Karp Judith E; Gojo Ivana; Telford William G; Lee Min-Jung; Kong Hye Sik; Trepel Jane B
Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
Annals of clinical and laboratory science 2005;35(4):397-406.
-
2004: Rice Anna M; Holtz Kathleen M; Karp Judith; Rollins Sandra; Sartorelli Alan C
Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia.
Leukemia research 2004;28(11):1227-37.
-
2004: Chen Wenyong; Cooper Timothy K; Zahnow Cynthia A; Overholtzer Michael; Zhao Zhiquan; Ladanyi Marc; Karp Judith E; Gokgoz Nalan; Wunder Jay S; Andrulis Irene L; Levine Arnold J; Mankowski Joseph L; Baylin Stephen B
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.
Cancer cell 2004;6(4):387-98.
-
2004: Raponi Mitch; Belly Robert T; Karp Judith E; Lancet Jeffrey E; Atkins David; Wang Yixin
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.
BMC cancer 2004;4():56.
-
2004: Ray Sutapa; Lu Ying; Kaufmann Scott H; Gustafson W Clay; Karp Judith E; Boldogh Istvan; Fields Alan P; Brasier Allan R
Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.
The Journal of biological chemistry 2004;279(34):35604-15.
-
2004: O'Farrell Anne-Marie; Yuen Helene A; Smolich Beverly; Hannah Alison L; Louie Sharianne G; Hong Weiru; Stopeck Alison T; Silverman Lewis R; Lancet Jeffrey E; Karp Judith E; Albitar Maher; Cherrington Julie M; Giles Francis J
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 2004;28(7):679-89.
-
2004: Karp Judith E; Gojo Ivana; Pili Roberto; Gocke Christopher D; Greer Jacqueline; Guo Chuanfa; Qian David; Morris Lawrence; Tidwell Michael; Chen Helen; Zwiebel James
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3577-85.
-
2004: Bolaños-Meade Javier; Guo Chuanfa; Gojo Ivana; Karp Judith E
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Leukemia research 2004;28(6):571-7.
-
2004: Nandi Asit; Tidwell Michael; Karp Judith; Rapoport Aaron P
Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells.
Blood cells, molecules & diseases 2004;32(1):240-5.
-
2004: Karp J E; Lancet J E
Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
Annals of hematology 2004;83 Suppl 1():S87-8.
-
2003: Smith B Douglas; Karp Judith E
Ribonucleotide reductase: an old target with new potential.
Leukemia research 2003;27(12):1075-6.
-
2003: Chandra Joya; Hackbarth Jennifer; Le Son; Loegering David; Bone Nancy; Bruzek Laura M; Narayanan Ven L; Adjei Alex A; Kay Neil E; Tefferi Ayalew; Karp Judith E; Sausville Edward A; Kaufmann Scott H
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
Blood 2003;102(13):4512-9.
-
2003: Lancet Jeffrey E; Karp Judith E
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
Blood 2003;102(12):3880-9.
-
2003: Greene Marianne E; Mundschau Gina; Wechsler Joshua; McDevitt Michael; Gamis Alan; Karp Judith; Gurbuxani Sandeep; Arceci Robert; Crispino John D
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Blood cells, molecules & diseases 2003;31(3):351-6.
-
2003: Meng Xue Wei; Chandra Joya; Loegering David; Van Becelaere Keri; Kottke Timothy J; Gore Steven D; Karp Judith E; Sebolt-Leopold Judy; Kaufmann Scott H
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro.
The Journal of biological chemistry 2003;278(47):47326-39.
-
2003: Lancet Jeffrey E; Karp Judith E
Farnesyl transferase inhibitors in myeloid malignancies.
Blood reviews 2003;17(3):123-9.
-
2003: Nakanishi Takeo; Karp Judith E; Tan Ming; Doyle L Austin; Peters Todd; Yang Weidong; Wei David; Ross Douglas D
Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3320-8.
-
2003: Giles Francis J; Stopeck Alison T; Silverman Lewis R; Lancet Jeffrey E; Cooper Maureen A; Hannah Alison L; Cherrington Julie M; O'Farrell Anne-Marie; Yuen Helene A; Louie Sharianne G; Hong Weiru; Cortes Jorge E; Verstovsek Srdan; Albitar Maher; O'Brien Susan M; Kantarjian Hagop M; Karp Judith E
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
-
2003: Smith B Douglas; Karp Judith; Burke Philip
Response to 'comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial'.
British journal of haematology 2003;122(1):164-5.
-
2003: Edelman Martin J; Bauer Kenneth; Khanwani Shyam; Tait Nancy; Trepel Jane; Karp Judith; Nemieboka Noble; Chung Eun-Joo; Van Echo David
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
Cancer chemotherapy and pharmacology 2003;51(5):439-44.
-
2003: Giles Francis J; Cooper Maureen A; Silverman Lewis; Karp Judith E; Lancet Jeffrey E; Zangari Maurizio; Shami Paul J; Khan Khuda D; Hannah Alison L; Cherrington Julie M; Thomas Deborah A; Garcia-Manero Guillermo; Albitar Maher; Kantarjian Hagop M; Stopeck Alison T
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
-
2003: Bolaños-Meade Javier; Karp Judith E; Guo Chuanfa; Sarkodee-Adoo Clarence B; Rapoport Aaron P; Tidwell Michael L; Buddharaju Laxmi N; Chen T Timothy
Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.
Leukemia research 2003;27(4):313-21.
-
2003: Karp Judith E; Ross Douglas D; Yang Weidong; Tidwell Michael L; Wei Yuetong; Greer Jacqueline; Mann Dean L; Nakanishi Takeo; Wright John J; Colevas A Dmitri
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):307-15.
-
2002: Wechsler Joshua; Greene Marianne; McDevitt Michael A; Anastasi John; Karp Judith E; Le Beau Michelle M; Crispino John D
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Nature genetics 2002;32(1):148-52.
-
2002: Chung Eun Joo; Hwang Sang-Gu; Nguyen PhuongMai; Lee Sunmin; Kim Jung-Sik; Kim Jin Woo; Henkart Pierre A; Bottaro Donald P; Soon Lilian; Bonvini Paolo; Lee Su-Jae; Karp Judith E; Oh Ho Jung; Rubin Jeffrey S; Trepel Jane B
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin.
Blood 2002;100(3):982-90.
-
2002: Lancet Jeffrey E; Rosenblatt Joseph D; Karp Judith E
Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.
Seminars in hematology 2002;39(3 Suppl 2):31-5.
-
2002: Sotomayor E M; Piantadosi S; Miller C B; Karp J E; Jones R J; Rowley S D; Kaufmann S H; Braine H; Burke P J; Gore S D
Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.
Leukemia research 2002;26(5):461-71.
-
2002: Karp Judith E; Mookerjee Bijoyesh P
Overcoming drug resistance: targeting more than one site.
Leukemia research 2002;26(1):107-9.
-
2001: Karp J E; Kaufmann S H; Adjei A A; Lancet J E; Wright J J; End D W
Current status of clinical trials of farnesyltransferase inhibitors.
Current opinion in oncology 2001;13(6):470-6.
-
2001: Brodsky R A; Sensenbrenner L L; Smith B D; Dorr D; Seaman P J; Lee S M; Karp J E; Brodsky I; Jones R J
Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia.
Annals of internal medicine 2001;135(7):477-83.
-
2001: Karp J E
Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Seminars in hematology 2001;38(3 Suppl 7):16-23.
-
2001: Karp J E; Lancet J E; Kaufmann S H; End D W; Wright J J; Bol K; Horak I; Tidwell M L; Liesveld J; Kottke T J; Ange D; Buddharaju L; Gojo I; Highsmith W E; Belly R T; Hohl R J; Rybak M E; Thibault A; Rosenblatt J
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Blood 2001;97(11):3361-9.
-
2001: Karp J E
MDR modulation in acute myelogenous leukemia: is it dead?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(4):666-7.
-
2001: Gojo I; Karp J E
The impact of biology on the treatment of secondary AML.
Cancer treatment and research 2001;108():231-55.
-
2001: Samaniego F; Pati S; Karp J E; Prakash O; Bose D
Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation?
Journal of the National Cancer Institute. Monographs 2001;(28):15-23.
-
2000: Svingen P A; Karp J E; Krajewski S; Mesner P W; Gore S D; Burke P J; Reed J C; Lazebnik Y A; Kaufmann S H
Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia.
Blood 2000;96(12):3922-31.
-
2000: Haga S B; Fu S; Karp J E; Ross D D; Williams D M; Hankins W D; Behm F; Ruscetti F W; Chang M; Smith B D; Becton D; Raimondi S C; Berg P E
BP1, a new homeobox gene, is frequently expressed in acute leukemias.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(11):1867-75.
-
2000: Ross D D; Karp J E; Chen T T; Doyle L A
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia.
Blood 2000;96(1):365-8.
-
2000: Sarkodee-Adoo C B; Merz W G; Karp J E
Management of infections in patients with acute leukemia.
Oncology (Williston Park, N.Y.) 2000;14(5):659-66, 671-2; discussion 672-7.
-
2000: Karp J E; Sarkodee-Adoo C B
Therapy-related acute leukemia.
Clinics in laboratory medicine 2000;20(1):71-81, ix.
-
1999: Samaniego F; Bryant J L; Liu N; Karp J E; Sabichi A L; Thierry A; Lunardi-Iskandar Y; Gallo R C
Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin.
Journal of the National Cancer Institute 1999;91(2):135-43.
-
1998: Karp J E; Merz W G
Randomized trial of lipid-based amphotericin B for invasive aspergillosis in neutropenic hosts is an important step forward.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(6):1413-4.
-
1998: Kaufmann S H; Gore S D; Miller C B; Jones R J; Zwelling L A; Schneider E; Burke P J; Karp J E
Topoisomerase II and the response to antileukemic therapy.
Leukemia & lymphoma 1998;29(3-4):217-37.
-
1998: Kaufmann S H; Karp J E; Svingen P A; Krajewski S; Burke P J; Gore S D; Reed J C
Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.
Blood 1998;91(3):991-1000.
-
1998: Karp J E
Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS-related leukemias.
Current opinion in oncology 1998;10(1):3-9.
-
1997: Kelloff G J; Hawk E T; Karp J E; Crowell J A; Boone C W; Steele V E; Lubet R A; Sigman C C
Progress in clinical chemoprevention.
Seminars in oncology 1997;24(2):241-52.
-
1997: Karp J E; Smith M A
The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention.
Seminars in oncology 1997;24(1):103-13.
-
1996: Karp J E; Chiarodo A; Brawley O; Kelloff G J
Prostate cancer prevention: investigational approaches and opportunities.
Cancer research 1996;56(24):5547-56.
-
1996: Karp J E; Smith M A
Modifying risks of secondary leukemias: is drug scheduling important?
Journal of the National Cancer Institute 1996;88(24):1787-9.
-
1996: Karp J E; Pluda J M; Yarchoan R
AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches.
Hematology/oncology clinics of North America 1996;10(5):1031-49.
-
1996: Kaufmann S H; Karp J E; Burke P J; Gore S D
Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study.
Leukemia & lymphoma 1996;23(1-2):71-83.
-
1996: Smith M A; McCaffrey R P; Karp J E
The secondary leukemias: challenges and research directions.
Journal of the National Cancer Institute 1996;88(7):407-18.
-
1995: Karp J E; Broder S
Molecular foundations of cancer: new targets for intervention.
Nature medicine 1995;1(4):309-20.
-
1995: Kaufmann S H; Charron M; Burke P J; Karp J E
Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo.
Cancer research 1995;55(6):1255-60.
-
1995: Schneider E; Cowan K H; Bader H; Toomey S; Schwartz G N; Karp J E; Burke P J; Kaufmann S H
Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia.
Blood 1995;85(1):186-93.
-
1995: Broder S; Karp J E
Progress against cancer.
Journal of cancer research and clinical oncology 1995;121(11):633-47.
-
1994: Geller R B; Karp J E
Adult acute leukemia: a need for continued translational research.
Blood 1994;84(11):3980-1.
-
1994: Karp J E; McCaffrey R P
New avenues of translational research in leukemia and lymphoma: outgrowth of a Leukemia Society of America-National Cancer Institute workshop.
Journal of the National Cancer Institute 1994;86(16):1196-201.
-
1994: Karp J E; Broder S
Oncology and hematology.
JAMA : the journal of the American Medical Association 1994;271(21):1693-5.
-
1994: Karp J E; Broder S
New directions in molecular medicine.
Cancer research 1994;54(3):653-65.
-
1994: Kaufmann S H; Karp J E; Jones R J; Miller C B; Schneider E; Zwelling L A; Cowan K; Wendel K; Burke P J
Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
Blood 1994;83(2):517-30.
-
1993: Wingard J R; Merz W G; Rinaldi M G; Miller C B; Karp J E; Saral R
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.
Antimicrobial agents and chemotherapy 1993;37(9):1847-9.
-
1993: Karp J E; Broder S
Oncology.
JAMA : the journal of the American Medical Association 1993;270(2):237-9.
-
1993: Pluda J M; Venzon D J; Tosato G; Lietzau J; Wyvill K; Nelson D L; Jaffe E S; Karp J E; Broder S; Yarchoan R
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1099-107.
-
1993: Karp J E; Dick J D
Emergence of gram-positive infections: relationship to indwelling catheters and management during chemotherapy-induced aplasia.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;132():221-9.
-
1993: Broder S; Karp J E
Workshop on Taxol and Taxus. Introduction.
Journal of the National Cancer Institute. Monographs 1993;(15):1-4.
-
1992: Karp J E; Broder S
The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention.
Leukemia & lymphoma 1992;8(3):167-88.
-
1992: Karp J E; Broder S
Oncology.
JAMA : the journal of the American Medical Association 1992;268(3):391-3.
-
1992: Broder S; Karp J E
The expanding challenge of HIV-associated malignancies.
CA: a cancer journal for clinicians 1992;42(2):69-73.
-
1991: Horn T D; Rest E B; Karp J E; Burke P J; Vogelsang G B; Boucher C L; Hood A F
Interleukin 2 and granulocyte-macrophage colony-stimulating factor induce a perivascular lymphocytic infiltrate in a skin explant model.
Archives of dermatology 1991;127(12):1789-93.
-
1991: Nayfield S G; Karp J E; Ford L G; Dorr F A; Kramer B S
Potential role of tamoxifen in prevention of breast cancer.
Journal of the National Cancer Institute 1991;83(20):1450-9.
-
1991: Wingard J R; Merz W G; Rinaldi M G; Johnson T R; Karp J E; Saral R
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
The New England journal of medicine 1991;325(18):1274-7.
-
1991: Karp J E; Broder S
Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas.
Cancer research 1991;51(18):4743-56.
-
1991: Karp J E; Merz W G; Charache P
Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia.
Reviews of infectious diseases 1991;13(4):592-9.
-
1991: Karp J E; Merz W G; Dick J D; Saral R
Strategies to prevent or control infections after bone marrow transplants.
Bone marrow transplantation 1991;8(1):1-6.
-
1991: Kaufmann S H; McLaughlin S J; Kastan M B; Liu L F; Karp J E; Burke P J
Topoisomerase II levels during granulocytic maturation in vitro and in vivo.
Cancer research 1991;51(13):3534-43.
-
1991: Karp J E; Broder S
Oncology.
JAMA : the journal of the American Medical Association 1991;265(23):3141-3.
-
1991: Kimes B W; Cairoli V; Freireich E J; Karp J; Yang S S
Training in clinical research in oncology.
Cancer research 1991;51(3):753-6.
-
1991: Horn T D; Kerker B J; Karp J E; Burke P J; Hood A F
Endothelial expression of intercellular adhesion molecule (ICAM-1) is unaffected by marrow aplasia-inducing chemotherapy.
Journal of cutaneous pathology 1991;18(1):36-9.
-
1991: Horn T D; Burke P J; Karp J E; Hood A F
Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption.
Archives of dermatology 1991;127(1):49-52.
-
1990: Geller R B; Zahurak M; Hurwitz C A; Burke P J; Karp J E; Piantadosi S; Civin C I
Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10)
British journal of haematology 1990;76(3):340-7.
-
1990: Karp J E; Burke P J; Donehower R C
Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(8):553-6.
-
1990: Karp J E; Merz W G; Dick J D; Saral R; Burke P J
Management of infectious complications of acute leukemia and antileukemia therapy.
Oncology (Williston Park, N.Y.) 1990;4(7):45-53; discussion 53-4.
-
1990: Geller R B; Saral R; Karp J E; Santos G W; Burke P J
Cure of acute myelocytic leukemia in adults: a reality.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(5):313-5.
-
1989: Horn T D; Redd J V; Karp J E; Beschorner W E; Burke P J; Hood A F
Cutaneous eruptions of lymphocyte recovery.
Archives of dermatology 1989;125(11):1512-7.
-
1989: Geller R B; Burke P J; Karp J E; Humphrey R L; Braine H G; Tucker R W; Fox M G; Zahurak M; Morrell L; Hall K L
A two-step timed sequential treatment for acute myelocytic leukemia.
Blood 1989;74(5):1499-506.
-
1989: Burke P J; Karp J E; Geller R B; Vaughan W P
Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(10):692-4.
-
1989: Geller R B; Boone L B; Karp J E; Davidson N; Selonick S E; Edwards J; Burke P J
Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy.
Cancer 1989;64(3):629-34.
-
1989: Rowinsky E K; Burke P J; Karp J E; Tucker R W; Ettinger D S; Donehower R C
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Cancer research 1989;49(16):4640-7.
-
1989: Hantel A; Dick J D; Karp J E
Listeriosis in the setting of malignant disease. Changing issues in an unusual infection.
Cancer 1989;64(2):516-20.
-
1989: Guyer D R; Schachat A P; Vitale S; Markowitz J A; Braine H; Burke P J; Karp J E; Graham M
Leukemic retinopathy. Relationship between fundus lesions and hematologic parameters at diagnosis.
Ophthalmology 1989;96(6):860-4.
-
1989: Schachat A P; Markowitz J A; Guyer D R; Burke P J; Karp J E; Graham M L
Ophthalmic manifestations of leukemia.
Archives of ophthalmology 1989;107(5):697-700.
-
1989: Karp J E; Donehower R C; Enterline J P; Dole G B; Fox M G; Burke P J
In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia.
Blood 1989;73(1):24-30.
-
1988: Mitchell R B; Wagner J E; Karp J E; Watson A J; Brusilow S W; Przepiorka D; Storb R; Santos G W; Burke P J; Saral R
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases.
The American journal of medicine 1988;85(5):662-7.
-
1988: Merz W G; Karp J E; Hoagland M; Jett-Goheen M; Junkins J M; Hood A F
Diagnosis and successful treatment of fusariosis in the compromised host.
The Journal of infectious diseases 1988;158(5):1046-55.
-
1988: Vaughan W P; Civin C I; Weisenburger D D; Karp J E; Graham M L; Sanger W G; Grierson H L; Joshi S S; Burke P J
Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1988;2(10):661-6.
-
1988: Karp J E; Burch P A; Merz W G
An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis.
The American journal of medicine 1988;85(2):203-6.
-
1988: Hurwitz C A; Loken M R; Graham M L; Karp J E; Borowitz M J; Pullen D J; Civin C I
Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.
Blood 1988;72(1):299-307.
-
1988: Kuhlman J E; Fishman E K; Burch P A; Karp J E; Zerhouni E A; Siegelman S S
CT of invasive pulmonary aspergillosis.
AJR. American journal of roentgenology 1988;150(5):1015-20.
-
1988: Karp J E; Dick J D; Merz W G
Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient.
European journal of cancer & clinical oncology 1988;24 Suppl 1():S5-13.
-
1988: Dick J D; Shull V; Karp J E; Valentine J
Bacterial and host factors affecting Pseudomonas aeruginosa colonization versus bacteremia in granulocytopenic patients.
European journal of cancer & clinical oncology 1988;24 Suppl 1():S47-54.
-
1987: Burch P A; Karp J E; Merz W G; Kuhlman J E; Fishman E K
Favorable outcome of invasive aspergillosis in patients with acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(12):1985-93.
-
1987: Roubenoff R; Jones R J; Karp J E; Stevens M B
Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA.
Arthritis and rheumatism 1987;30(10):1187-90.
-
1987: Walling D M; McGraw D J; Merz W G; Karp J E; Hutchins G M
Disseminated infection with Trichosporon beigelii.
Reviews of infectious diseases 1987;9(5):1013-9.
-
1987: Kuhlman J E; Fishman E K; Burch P A; Karp J E; Zerhouni E A; Siegelman S S
Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management.
Chest 1987;92(1):95-9.
-
1987: Karp J E; Donehower R C; Burke P J
An in vitro model to predict clinical response in adult acute myelogenous leukemia.
Seminars in oncology 1987;14(2 Suppl 1):172-81.
-
1987: Winston D J; Ho W G; Champlin R E; Karp J; Bartlett J; Finley R S; Joshi J H; Talbot G; Levitt L; Deresinski S
Norfloxacin for prevention of bacterial infections in granulocytopenic patients.
The American journal of medicine 1987;82(6B):40-6.
-
1987: Karp J E; Donehower R C; Dole G B; Burke P J
Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
Blood 1987;69(4):1134-40.
-
1987: Burke P J; Karp J E
Relationship of the hematopoietic cycle to the combined activities of a stimulator and a short-lived inhibitor.
Blood 1987;69(2):513-21.
-
1987: Karp J E; Merz W G; Hendricksen C; Laughon B; Redden T; Bamberger B J; Bartlett J G; Saral R; Burke P J
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.
Annals of internal medicine 1987;106(1):1-7.
-
1986: Merz W G; Karp J E; Schron D; Saral R
Increased incidence of fungemia caused by Candida krusei.
Journal of clinical microbiology 1986;24(4):581-4.
-
1986: Donehower R C; Karp J E; Burke P J
Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.
Cancer treatment reports 1986;70(9):1059-65.
-
1986: Karp J E; Burke P J
Growth response of residual leukemia after initial drug therapy.
Cancer research 1986;46(8):4205-7.
-
1986: Karp J E; Dick J D; Angelopulos C; Charache P; Green L; Burke P J; Saral R
Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia.
The American journal of medicine 1986;81(2):237-42.
-
1986: Burke P J; Karp J E; Saylor P L
Drug induced host factors which stimulate growth of residual leukemia in Lewis x Brown Norway F1 (LEW-BN) rats.
Cancer research 1986;46(4 Pt 1):1813-6.
-
1986: Karp J E; Merz W G
Association of reduced total iron binding capacity and fungal infections in leukemic granulocytopenic patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(2):216-20.
-
1986: Karp J E; Merz W G; Hendricksen C; Laughon B; Redden T; Bamberger B J; Bartlett J G; Saral R; Burke P J
Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract.
Scandinavian journal of infectious diseases. Supplementum 1986;48():66-78.
-
1985: Watson A J; Chambers T; Karp J E; Risch V R; Walker W G; Brusilow S W
Transient idiopathic hyperammonaemia in adults.
Lancet 1985;2(8467):1271-4.
-
1985: Burke P J; Karp J E
Increased tumor growth and drug uptake predicts for response to continuous infusion high-dose cytarabine.
Seminars in oncology 1985;12(2 Suppl 3):55-9.
-
1984: de Ment S H; Smith R R; Karp J E; Merz W G
Pulmonary, cardiac, and thyroid involvement in disseminated Pseudallescheria boydii.
Archives of pathology & laboratory medicine 1984;108(11):859-61.
-
1984: Karp J E; Donehower R C; Dole G B; Burke P J
Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism.
Cancer research 1984;44(11):5046-50.
-
1984: Vaughan W P; Karp J E; Burke P J
Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia.
Blood 1984;64(5):975-80.
-
1984: Karp J E; Burke P J; Saylor P L; Humphrey R L
Correlation of proliferative and clonogenic tumor cells in multiple myeloma.
Cancer research 1984;44(9):4197-200.
-
1984: Vaughan W P; Karp J E; Burke P J
Probable cures of adult acute leukemia using short term intensive investigational chemotherapy.
The Nebraska medical journal 1984;69(8):264-8.
-
1984: Markman M; Braine H G; Bias W B; Karp J E
Human histocompatibility antigens and survival in acute myelocytic leukemia.
Cancer 1984;53(7):1515-7.
-
1983: Foucar K; Vaughan W P; Armitage J O; Patil S; Dick F; Karp J E
Postleukemic dysmyelopoiesis.
American journal of hematology 1983;15(4):321-34.
-
1983: Karp J E; Shadduck R K; Burke P J; Shaper J H
The relationship between humoral stimulating activity and colony stimulating factor.
Experimental hematology 1983;11(7):639-48.
-
1983: Vaughan W P; Karp J E; Burke P J
Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1983;1(3):204-7.
-
1982: Burke P J; Vaughan W P; Karp J E; Saylor P L
The correlation of maximal drug dose, tumor recruitment, and sequence timing with therapeutic advantage: schedule-dependent toxicity of cytosine arabinoside.
Medical and pediatric oncology 1982;10 Suppl 1():201-8.
-
1982: Burke P J; Karp J E; Vaughan W P; Sanford P L
Recruitment of quiescent tumor by humoral stimulatory activity: requirements for successful chemotherapy.
Blood cells 1982;8(3):519-33.
-
1981: Vaughan W P; Kimball A W; Karp J E; Dragon L H; Burke P J
Factors affecting survival of patients with acute myelocytic leukemia presenting with high wbc counts.
Cancer treatment reports 1981;65(11-12):1007-13.
-
1981: Elfenbein G; Kallman C; Braine H; Bias W; Tutschka P; Karp J; Burke P; Wharam M; Saral R; Kaizer H; Mellits E; Santos G
Analysis of factors related to bone marrow graft rejection in aplastic anemia: usefulness of measures of broad alloimmunity as predictors.
Transplantation proceedings 1981;13(3):1539-43.
-
1981: Burke P J; Karp J E; Vaughan W P
Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
Journal of the National Cancer Institute 1981;67(3):529-38.
-
1981: Vaughan W P; Karp J E; Burke P J
Acute leukemia: early recognition can spell survival.
Geriatrics 1981;36(6):32-6.
-
1981: Karp J E; Humphrey R L; Burke P J
Timed sequential chemotherapy of cytoxan-refractory multiple myeloma with cytoxan and adriamycin based on induced tumor proliferation.
Blood 1981;57(3):468-75.
-
1980: Burke P J; Vaughan W P; Karp J E
A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation.
Blood 1980;55(6):960-8.
-
1980: Vaughan W P; Karp J E; Burke P J
Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia.
Cancer 1980;45(5):859-65.
-
1980: Karp J E; Garvin C C; Burke P J
Isokinetic gradient sedimentation of normal human bone marrow cells: a simple method for isolation of proliferative granulocytic and erythroid elements.
Journal of the National Cancer Institute 1980;64(2):249-53.
-
1978: Karp J E; Schacter L P; Burke P J
Humoral factors in aplastic anemia: relationship of liver dysfunction to lack of serum stimulation of bone marrow growth in vitro.
Blood 1978;51(3):397-414.
-
1978: Ettinger D S; Karp J E; Abeloff M D; Burke P J; Braine H G
Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung.
Cancer treatment reports 1978;62(3):413-24.
-
1977: Burke P J; Karp J E; Braine H G; Vaughan W P
Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.
Cancer research 1977;37(7 Pt 1):2138-46.
-
1977: Karp J E; Burke P J; Humphrey R L
Induction of serum stimulation and plasma cell proliferation during chemotherapy of multiple myeloma.
Blood 1977;49(6):925-34.
-
1976: Karp J E; Burke P J
Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation.
Cancer research 1976;36(10):3600-3.
-
1976: Karp J E; Burke P J
Influence of humoral regulators on proliferation and maturation of normal and leukemic cells.
Cancer research 1976;36(5):1674-9.
Sign-in to see more
